IRAK4-IN-20

立即咨询

IRAK4-IN-20

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1931994-80-7

IRAK4-IN-20 (Compound BAY-1834845) 是一种具有口服活性的IRAK4抑制剂，IC₅₀为 3.55 nM。 IRAK4-IN-20 可用于急性呼吸窘迫综合征 (ARDS) 的研究。

生物活性

IRAK4-IN-20 (Compound BAY-1834845) is an orally activeIRAK4inhibitor with anIC₅₀of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research^[1].

IC₅₀& Target

IRAK4

3.55 nM (IC₅₀)

体外研究
(In Vitro)

IRAK4-IN-20 (Compound BAY-1834845) (500 nM, 20 h) decreases inflammatory cytokines secretion effectively in an in vitro treatment of LPS stimulated human peripheral blood mononuclear cells (PBMC)^[1].

体内研究
(In Vivo)

IRAK4-IN-20 (Compound BAY-1834845) (150 mg/kg; p.o.; once or twice) effectively prevents acute respiratory distress syndrome in mice^[1].

Animal Model:	Female Balb/c mice (aged 6–7 weeks), LPS-induced ARDS mouse model^[1]
Dosage:	150 mg/kg
Administration:	Oral administration, 30 min before LPS modeling or twice 4 h and 12 h after LPS modeling
Result:	Remarkably decreased inflammatory cells infiltrating lung tissue and neutrophil count in BALF. Effectively reduced the numbers of total T cells, monocyte, and macrophages. Largely preserved the signatures of naive lymphocytes and stromal cells such as endothelial cells, chondrocytes, and smooth muscle cells. Regulated inflammation and innate immunity genes more efficiently than Dexamethasone (HY-14648).

分子量

450.45

Formula

C₂₂H₂₅F₃N₄O₃

CAS 号

1931994-80-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.